title: [The significance of deletion polymorphism in the ACE gene for progression of diabetic nephropathies treated with ACE inhibitors].
abstract: The aim of the study was to evaluate the effect of an insertion/deletion polymorphism of the angiotensin converting enzyme (ACE) gene on progression of diabetic nephropathy. We performed an observational follow-up study of 35 patients with insulin-dependent diabetes and diabetic nephropathy. Patients were investigated during captopril treatment for a median of seven (range three to nine) years. Eleven patients were homozygous for the deletion allele (DD) and 24 were hetero- or homozygous for the insertion allele (ID + II). The two groups had comparable glomerular filtration rate, albuminuria and blood pressure at baseline and captopril induced nearly the same mean reduction in blood pressure--to 103 (SD 5) mm Hg in the DD-group and 102 (8) mm Hg in the ID + II-group. The rate of decline in glomerular filtration rate was significantly steeper in the DD group than in the other group (mean 5.7 (SD 3.7) versus 2.6 (2.8) ml/min/year, p = 0.01). In conclusion, the deletion polymorphism in the ACE gene reduces the long term beneficial effect of ACE inhibition on the progression of diabetic nephropathy in patients with insulin dependent diabetes.
authors.affiliation: Steno Diabetes Center, Gentofte.
authors.forename: L
authors.initials: L
authors.lastname: Tarnow
authors.forename: H H
authors.initials: HH
authors.lastname: Parving
authors.forename: P
authors.initials: P
authors.lastname: Jacobsen
authors.forename: P
authors.initials: P
authors.lastname: Rossing
authors.forename: L
authors.initials: L
authors.lastname: Lecerf
authors.forename: O
authors.initials: O
authors.lastname: Poirier
authors.forename: F
authors.initials: F
authors.lastname: Cambien
mesh_terms: D000328:Adult; D000483:Alleles; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use*; D002872:Chromosome Deletion; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000235:genetics; D003928:Diabetic Nephropathies / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic; D011379:Prognosis
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril; D007703:Peptidyl-Dipeptidase A